Immunosuppression in Transplantation: Balancing Efficacy and Long-Term Outcomes

Background: Immunosuppressive therapy is critical for preventing graft rejection in transplant recipients, but long-term use is associated with significant complications, including infections and malignancies. Objectives: This narrative review evaluates the evolution of immunosuppressive strategies in transplantation, focusing on achieving a balance between efficacy and long-term patient safety. Methods: We reviewed clinical trials and observational studies from 2012 to 2024, focusing on calcineurin inhibitors, mTOR inhibitors, and novel biologics in renal and liver transplantation. Results: Modern protocols combining tacrolimus with mycophenolate mofetil have reduced acute rejection rates to below 10%. However, long-term use increases the risk of nephrotoxicity and infections by 25%. Emerging biologics, such as belatacept, show promise in reducing these risks but are limited by high costs and variable efficacy in high-risk patients. Conclusion: Tailored immunosuppression regimens that minimize toxicity while preventing rejection are essential for improving long-term outcomes. Future research should focus on personalized medicine approaches and the development of cost-effective biologics.